[go: up one dir, main page]

IN2014MN00357A - - Google Patents

Info

Publication number
IN2014MN00357A
IN2014MN00357A IN357MUN2014A IN2014MN00357A IN 2014MN00357 A IN2014MN00357 A IN 2014MN00357A IN 357MUN2014 A IN357MUN2014 A IN 357MUN2014A IN 2014MN00357 A IN2014MN00357 A IN 2014MN00357A
Authority
IN
India
Prior art keywords
hydrophobic
peptides
peptide
yrfli
irfli
Prior art date
Application number
Other languages
English (en)
Inventor
Michael John Gait
Andrey Alexandrovich Arzumanov
Amer F Saleh
Matthew J A Wood
Corinne Betts
Taeyoung Koo
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1115014.1A external-priority patent/GB201115014D0/en
Priority claimed from GBGB1211740.4A external-priority patent/GB201211740D0/en
Application filed by Medical Res Council filed Critical Medical Res Council
Publication of IN2014MN00357A publication Critical patent/IN2014MN00357A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003Peptide-nucleic acids (PNAs)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
IN357MUN2014 2011-08-30 2012-08-29 IN2014MN00357A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161528804P 2011-08-30 2011-08-30
GBGB1115014.1A GB201115014D0 (en) 2011-08-30 2011-08-30 Peptides
GBGB1211740.4A GB201211740D0 (en) 2012-07-03 2012-07-03 Peptides
PCT/GB2012/052116 WO2013030569A2 (fr) 2011-08-30 2012-08-29 Peptides

Publications (1)

Publication Number Publication Date
IN2014MN00357A true IN2014MN00357A (fr) 2015-06-19

Family

ID=47756980

Family Applications (1)

Application Number Title Priority Date Filing Date
IN357MUN2014 IN2014MN00357A (fr) 2011-08-30 2012-08-29

Country Status (10)

Country Link
US (1) US9302014B2 (fr)
EP (1) EP2751128B1 (fr)
JP (1) JP6077543B2 (fr)
CN (1) CN103998458B (fr)
AU (1) AU2012300633B2 (fr)
BR (1) BR112014004902B1 (fr)
CA (1) CA2846218C (fr)
ES (1) ES2876939T3 (fr)
IN (1) IN2014MN00357A (fr)
WO (1) WO2013030569A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1231425A1 (zh) 2014-01-13 2017-12-22 Berg Llc 烯醇酶1(eno1)組合物及其用途
CN107073063A (zh) * 2014-06-06 2017-08-18 帷幄生物技术公司 用于修复软骨损伤的方法
CN106390100B (zh) * 2015-01-28 2021-06-22 中国科学院天津工业生物技术研究所 一种多肽复合物作为glp-1药物载体的应用、方法及其融合蛋白复合物
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
CA3010599C (fr) * 2016-01-06 2025-05-20 Stealth Biotherapeutics Inc. Méthodes et compositions pour la prévention et le traitement d'une dystrophie musculaire de duchenne
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
SG11201809468XA (en) 2016-04-29 2018-11-29 Sarepta Therapeutics Inc Oligonucleotide analogues targeting human lmna
CN109563144B (zh) 2016-06-01 2023-03-28 雅斯娜 化合物
KR102824513B1 (ko) 2016-07-05 2025-06-25 바이오마린 테크놀로지스 비.브이. 유전적 장애 치료를 위한, 특징이 개선된, 비사이클릭 스캐폴드 모이어티를 포함하는 프리-mrna 스플라이스 스위칭 또는 조정 올리고뉴클레오티드
MX2019008199A (es) 2017-01-06 2019-11-25 Avidity Biosciences Llc Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
WO2018150196A1 (fr) * 2017-02-17 2018-08-23 Oxford University Innovation Limited Peptides de pénétration cellulaire modifiés par glycosylation
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
TW201919682A (zh) 2017-08-08 2019-06-01 西班牙商阿爾米雷爾有限公司 活化Nrf2路徑的新穎化合物
WO2019070962A1 (fr) * 2017-10-04 2019-04-11 Ohio State Innovation Foundation Inhibiteurs peptidiques bicycliques
CN108070025B (zh) * 2017-10-24 2019-11-19 中山大学附属口腔医院 一种细胞穿透肽和细胞穿透肽复合物及二者的应用
US11793884B2 (en) 2018-01-29 2023-10-24 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of CAL-PDZ binding domain
EP3784248A4 (fr) * 2018-04-26 2022-08-10 Sarepta Therapeutics, Inc. Oligomères induisant le saut d'exon et conjugués d'oligomères pour la dystrophie musculaire
WO2019226651A1 (fr) * 2018-05-22 2019-11-28 Children's Medical Center Corporation Nanoparticules pour le traitement de la néovascularisation choroïdienne et d'autres indications
GB201812980D0 (en) * 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812972D0 (en) * 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
CN113453723A (zh) 2018-12-07 2021-09-28 牛津大学科技创新有限公司 接头
CN113660938A (zh) * 2019-01-30 2021-11-16 国立研究开发法人国立精神·神经医疗研究中心 核酸递送复合物
GB201911403D0 (en) * 2019-08-09 2019-09-25 Univ Oxford Innovation Ltd Conjugate and uses thereof
EP4370677A1 (fr) 2021-07-16 2024-05-22 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Oligonucléotide pour inhiber l'activité de tremblement
US20240390508A1 (en) 2021-08-21 2024-11-28 Takeda Pharmaceutical Company Limited Human transferrin receptor binding peptide-drug conjugate
WO2023214373A2 (fr) 2022-05-06 2023-11-09 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Oligonucléotide
GB202216207D0 (en) * 2022-11-01 2022-12-14 Univ Oxford Innovation Ltd Shortened cell-penetrating peptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002530059A (ja) 1998-11-13 2002-09-17 サイクラセル・リミテッド 輸送ベクター
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
WO2009005793A2 (fr) 2007-06-29 2009-01-08 Avi Biopharma, Inc. Conjugués peptidiques spécifiques d'un tissu et procédés
US20110130346A1 (en) 2008-05-30 2011-06-02 Isis Innovation Limited Peptide conjugates for delvery of biologically active compounds
EP2283029A1 (fr) * 2008-06-04 2011-02-16 Medical Research Council Peptides
US20120309684A1 (en) 2009-11-30 2012-12-06 Isis Innovation Limited Conjugates for delivery of biologically active compounds

Also Published As

Publication number Publication date
CA2846218C (fr) 2020-09-01
BR112014004902A2 (pt) 2017-07-04
JP2014526238A (ja) 2014-10-06
WO2013030569A2 (fr) 2013-03-07
BR112014004902B1 (pt) 2022-02-08
JP6077543B2 (ja) 2017-02-08
AU2012300633A8 (en) 2014-05-29
CA2846218A1 (fr) 2013-03-07
WO2013030569A3 (fr) 2013-06-13
AU2012300633B2 (en) 2017-04-27
CN103998458A (zh) 2014-08-20
AU2012300633A1 (en) 2014-03-06
US20140342992A1 (en) 2014-11-20
ES2876939T3 (es) 2021-11-15
EP2751128B1 (fr) 2021-03-03
EP2751128A2 (fr) 2014-07-09
US9302014B2 (en) 2016-04-05
CN103998458B (zh) 2018-10-09

Similar Documents

Publication Publication Date Title
IN2014MN00357A (fr)
NZ603732A (en) Cell-penetrating peptides and uses therof
BRPI0816405B8 (pt) complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
MX344219B (es) Productos farmaceuticos peptidicos mejorados para resistencia a insulina.
MX2014008468A (es) Complementacion funcional bipartita inducida por antigenos, dual.
WO2012158964A3 (fr) Substances pharmaceutiques peptidiques améliorées servant à lutter contre l'ostéoporose
MX2018013981A (es) Productos farmaceuticos peptidicos mejorados para la resistencia a la insulina.
SG10201811729PA (en) Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
EP2570430A3 (fr) Vaccins de peptide avec Seq ID No: 78, 41, 44, 46 or 48 pour cancers exprimant des antigènes associés aux tumeurs
WO2012012352A3 (fr) Peptides et protéines modifiés
JP2014224126A5 (fr)
MX2009013325A (es) Transfeccion y transduccion de plantas con base en nano acarreadores.
WO2011135222A3 (fr) Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles
Kawaguchi et al. Identification of cellular proteins interacting with octaarginine (R8) cell-penetrating peptide by photo-crosslinking
WO2014134509A3 (fr) Particules de glucane modifiées par un peptide et une amine pour la délivrance de charges thérapeutiques
IN2014DN09963A (fr)
MX2009007261A (es) Vacuna de peptido foxp3.
WO2011048503A3 (fr) Peptides qui se lient au récepteur de l'alpha-fetoprotéine (afp) et leurs utilisations
MX2010005816A (es) Epítopos de péptido de stat3.
MX365599B (es) Moleculas de transporte especificas de proteoglicano c4s.
MY151307A (en) Peptides having antimicrobial activity
SG10201809464RA (en) Antibody gene expression-secretion system
NZ603379A (en) Ect2 peptides and vaccines including the same
JP2011512364A5 (fr)
WO2013162948A3 (fr) Puce à peptides fluorés, procédé de détection utilisant une puce à peptides fluorés et procédé de formation d'une puce à peptides fluorés